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Repair of the injured spinal cord is a major challenge in medicine. The limited intrinsic
regenerative response mounted by adult central nervous system (CNS) neurons is further
hampered by astrogliosis, myelin debris and scar tissue that characterize the damaged
CNS. Improved axon regeneration and recovery can be elicited by targeting extrinsic
factors as well as by boosting neuron-intrinsic growth regulators. Our knowledge of the
molecular basis of intrinsic and extrinsic regulators of regeneration has expanded rapidly,
resulting in promising new targets to promote repair. Intriguingly certain neuron-intrinsic
growth regulators are emerging as promising targets to both stimulate growth and relieve
extrinsic inhibition of regeneration. This crossroads between the intrinsic and extrinsic
aspects of spinal cord injury is a promising target for effective therapies for this unmet
need.
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Introduction
The adult mammalian central nervous system (CNS) has a poor ability to regenerate and restore
function after injury. The pioneering work of Aguayo and colleagues showing that CNS neurons
can grow into peripheral nerve grafts, but stop when they re-encounter the CNS led to the
predominance of the hypothesis that the failure of axons to regenerate is attributed to the presence
of inhibitory factors in the CNS microenvironment (David and Aguayo, 1981; Yiu and He, 2006).
Indeed, it is now recognized that CNS myelin contains myelin-associated inhibitors (MAIs)
including Nogo, myelin-associated glycoprotein (MAG) and oligodendrocyte myelin glycoprotein
(OMgp) that collapse axonal growth cones and inhibit growth. The deposition of chondroitin
sulfate proteoglycans (CSPGs) by reactive astrocytes also presents a formidable barrier to axon
regeneration through sites of injury (Yiu and He, 2006). Targeting these extrinsic inhibitory
factors has led to modest improvements in axonal plasticity and functional recovery after CNS
injury. Important work spearheaded by Marie Filbin and colleagues revealed a critical role for
the intrinsic state of CNS neurons in mediating extrinsic inhibition of axon regeneration. Filbin
and colleagues demonstrated that an age-associated decline in neuronal cAMP underlies a gain of
sensitivity to myelin-mediated inhibition (Cai et al., 2001). The notion that the neuron-intrinsic
growth state can regulate the sensitivity of the injured axon to extrinsic factors is also supported
by the enhanced axon regeneration in the spinal cord that can be elicited by a preconditioning
lesion of the peripheral nerve processes (Mar et al., 2014a). More recently, it has been shown that
stimulating intrinsic growth potential by neuronal knockout of negative regulators of growth,
including phosphatase and tensin homolog (PTEN) and suppressor of cytokine signaling 3
(SOCS3), can induce striking long-distance axon regeneration after CNS injury (Liu et al., 2010;
Sun et al., 2011). Furthermore, engraftment of neural stem cells into transected rodent spinal
cords can result in impressive long-distance growth of grafted cells (Lu et al., 2012). These
studies provide proof-of-concept that robust neuron-intrinsic growth potential is able to overcome
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the inhibitory nature of the injured CNS. Here we will review
some novel therapeutic strategies that have been developed based
on our expanding knowledge of the molecular basis of intrinsic
axon growth and extrinsic outgrowth inhibition (Figure 1). We
will also highlight several recent examples of intrinsic regulators
that dually affect the neuronal response to the inhibitory
CNS environment. These findings have blurred the distinction
between an extrinsic or an intrinsic origin of CNS regeneration
failure and support the idea that a dynamic interplay between
the two determines whether an axon regenerates. A better
understanding of this crossroads between extrinsic and intrinsic
regulation of axon regeneration will contribute to the conception
of therapies to stimulate CNS repair.
Extrinsic Influences on Neural Repair
Myelin-associated Inhibitors
The identification of the inhibitory ligands and neuronal
receptors that mediate myelin-dependent inhibition of
regeneration has facilitated the development of selective
antagonists to neutralize the inhibitory effect of myelin proteins.
MAIs in CNS myelin bind to either paired immunoglobulin
repeat B (PirB; Atwal et al., 2008) or Nogo receptor (NgR), which
forms a complex with LINGO-1 (LRR and Ig containing Nogo
Receptor interacting protein) and p75NTR (p75 neurotrophin
receptor) or TROY (tumor necrosis factor receptor superfamily
member 19; Yiu and He, 2006). One strategy to target these
interactions has been to generate peptide mimics of ligands
to compete for receptor binding. An early example of this
is the Nogo extracellular peptide (NEP1–40), a peptide
derived from the Nogo-66 NgR-binding region of Nogo to
compete with the MAIs for NgR binding (Grandpré et al.,
2002). NEP1–40 was shown to abrogate Nogo-dependent
neurite outgrowth inhibition and promote corticospinal tract
regeneration after dorsal hemisection SCI (Grandpré et al.,
2002; Li and Strittmatter, 2003), but a later replication study did
not observe significant effects on axon regeneration (Steward
et al., 2008). Vaccines (Huang et al., 1999) and monoclonal
antibodies (Zörner and Schwab, 2010) have also been developed
to neutralize the MAIs, with reported improvements on
regeneration and functional recovery. However, deletion of NgR
or Nogo, MAG and OMgp in mice has had more variable effects
on regeneration and recovery (Zheng et al., 2003, 2005; Lee
et al., 2009, 2010; Cafferty et al., 2010). While deletion of Nogo
or NgR has negligible to modest effects on axon regeneration
after dorsal hemisection SCI, a unilateral pyramidotomy injury
to the CST results in an impressive collateral sprouting response
of uninjured axons into the denervated side of the spinal cord
(Cafferty and Strittmatter, 2006). Furthermore, a soluble NgR
decoy receptor, NgR(310)ecto-Fc that neutralizes Nogo, MAG,
and OMgp shows promise in promoting axonal sprouting and
functional recovery in acute and chronic SCI in rodents (Ji et al.,
2005; Li et al., 2005; Wang et al., 2011).
The Glial Scar
The astrocytic response to CNS injury is characterized by
the production of CSPGs, which present a potent barrier to
axon regeneration (Yiu and He, 2006). The inhibitory action
of CSPGs has been attributed to the abundance of negatively
charged glycosaminoglycan (GAG) chains that decorate the
protein core, which are thought to act as a poor substrate
and electrostatically repel growth cones. Protein tyrosine
phosphatase sigma (PTPsigma), leukocyte common antigen
related phosphatase (LAR) and NgR have been identified as
neuronal receptors that functionally interact with and mediate
CSPG-dependent inhibition of neuron growth (Shen et al., 2009;
Fisher et al., 2011; Dickendesher et al., 2012). Chondroitinase
ABC (chABC), a bacterial enzyme that digests the GAG chains,
abrogates CSPG-dependent neurite outgrowth inhibition in
vitro and improves neurite sprouting and functional recovery
after SCI (Bradbury et al., 2002). The efficacy of chABC
alone and in combination with other approaches in promoting
recovery after SCI has been independently confirmed in multiple
laboratories and is a promising approach for future translation
(Alilain et al., 2011; García-Alías et al., 2011; Lee et al.,
2012). Mechanistically, contrary to the view that CSPGs repel
growth cones, recent studies from the Silver group suggest
that CSPGs in fact tightly adhere to and confine growth
cones (Filous et al., 2014; Lang et al., 2015). After SCI, axons
closely associate with NG2, a transmembrane CSPG expressed
by a subset of oligodendrocyte progenitor cells. The presence
of synaptic markers at these sites of apposition suggests the
formation of stable ‘‘synapse-like’’ contacts between neurons and
NG2+ cells (Filous et al., 2014). Furthermore, DRG neurons
preferentially adhere to CSPG substrates in in vitro stripe
assays. Silver and colleagues propose a model whereby CSPGs
function to capture and arrest regenerating growth cones after
injury instead of repelling them (Filous et al., 2014). Perhaps
unexpectedly, deletion of NG2 in mice did not enhance axon
regeneration after dorsal column crush, but rather resulted in
more pronounced axonal dieback away from the injury site. This
was attributed to the loss of NG2-mediated capture of axons after
injury.
Pharmacological targeting of CSPG receptors is a strategy
to relieve CSPG-dependent capture of growth cones that has
shown potential in recent studies. Systemic administration
of cell-penetrating peptide mimetics of the extracellular and
intracellular regions of LAR by subcutaneous injection have been
shown to enhance serotonergic axon sprouting and functional
recovery after SCI in mice (Fisher et al., 2011). A recent report
from the Silver group demonstrates that PTPsigma can be
targeted in a similar fashion with a cell–permeable peptide,
termed intracellular sigma peptide (ISP), to enhance functional
recovery after contusive spinal cord injury in rats (Lang et al.,
2015). ISP was designed to bind to the cytoplasmic wedge
domain of PTPsigma. Using a CSPG gradient crossing assay,
Silver and colleagues provide evidence that PTPsigma-dependent
interactions with CSPGs maintain growth cones in a dystrophic
state and that treatment with ISP allows for growth cone
release. Based on the proposed mechanism that the interaction
between PTPsigma and CSPGs acts as a ‘‘molecular velcro’’, it
is surprizing that ISP is sufficient to overcome growth cone
immobilization because ISP targets the cytoplasmic domain of
PTPsigma, presumably sparing the physical interaction between
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FIGURE 1 | Overview of intrinsic and extrinsic molecules involved in
axon regeneration after CNS injury. Myelin debris from damaged
oligodendrocytes and chondroitin sulfate proteoglycans (CSPGs) produced by
reactive astrocytes interact with receptors on the growth cones to interfere with
axon extension. Intracellular signaling molecules regulate the ability of the
neuron to regenerate its damaged axon through the lesion environment. C3
transferase (Cethrin) inhibits RhoA to promote axon extension and cell survival.
Fasudil and Y-27632 inhibit Rho kinase (ROCK) to promote axon extension.
Bisperoxovanadium (bpV) inhibits phosphatase and tensin homolog (PTEN) to
promote neuroprotection. Rolipram inhibits phosphodiesterase 4 (PDE4) to
stabilize cAMP and promote axon extension. Microtubule stabilizers, taxol and
epothilones, reduce fibrotic scarring and promote axon extension.
Chondroitinase ABC (ChABC) digests CSPG glycosaminoglycan (GAG) chains
(in red), relieving CSPG-dependent growth inhibition. Intracellular sigma peptide
(ISP) inhibits protein tyrosine phosphatase sigma (PTPsigma) and
intracellular/extracellular leukocyte common antigen related phosphatase (LAR)
peptides (ILP/ELP) inhibit leukocyte antigen-related receptor (LAR) to neutralize
the inhibitory effect of CSPGs and promote axon sprouting. NgR(310)ecto-Fc
competes for binding to Nogo, myelin-associated glycoprotein (MAG) and
Oligodendrocyte myelin glycoprotein (OMgp) to relieve myelin-dependent
growth inhibition. Nogo extracellular peptide 1–40 (NEP1–40) competes for
NgR binding to neutralize inhibitory signaling through NgR.
CSPGs and the receptor. The relative contribution of the
receptor-ligand interaction and downstream signaling events to
growth cone immobilization remain unclear. Daily subcutaneous
injection of ISP following spinal cord contusion in rats resulted
in delayed beneficial outcomes, particularly in resumption of
bladder function (Lang et al., 2015). While these studies have
identified CSPG receptors as potential targets, future work could
focus on developing small molecule inhibitors to attain better
CNS penetrance and distribution for earlier and more efficient
targeting after injury. The idea that CSPGs are critical for growth
cone arrest suggests that these approaches may also be efficacious
in chronic SCI.
Intrinsic Influences on Neural Repair
The Conditioning Lesion
Injury to axons in the PNS is followed by neuronal expression
of regeneration-associated genes (RAGs), a response that is quite
limited in CNS neurons (Mar et al., 2014a). It has therefore
been hypothesized that a failure to initiate a growth program
contributes to unsuccessful regeneration in the CNS. The positive
effect of a peripheral conditioning lesion on CNS regeneration
has been attributed to the engagement of a RAG expression
response that stimulates growth (Blesch et al., 2012). One of these
RAGs, c-Jun, has been shown to be critical for axon regeneration,
as its deletion impairs axon regeneration and results in
exacerbated cell death after peripheral nerve injury in mice
(Raivich et al., 2004). The conditioning lesion has also recently
been shown to enhance the axonal transport of a multitude of
signaling and cytoskeleton regulators into the central process
(Mar et al., 2014b). Among these include members of the 14-3-3
adaptor proteins, which have important roles in neuroprotection,
axon guidance and cell growth (Shimada et al., 2013; Kaplan
et al., 2014). Elevation of cAMP is also a critical component
of the conditioning lesion effect and injection of cAMP into
dorsal root ganglia can mimic the pro-regeneration effect of
a conditioning lesion (Qiu et al., 2002). Interestingly, cAMP
also regulates the sensitivity of neurons to MAIs and CSPGs
(Cai et al., 2001). The Filbin group demonstrated that an
age-associated decline of neuronal cAMP correlates with an
acquisition of responsiveness to myelin-mediated inhibition of
growth and that pharmacological elevation of cAMP renders
adult neurons insensitive to myelin and CSPGs (Cai et al.,
2001). This reinforces the concept that extrinsic inhibitors rely
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on the intrinsic sensitivity of the neuron in order to inhibit
growth and suggests that targeting neuron-intrinsic signaling
can relieve the influence of the inhibitory microenvironment.
Supporting a direct link between cAMP and responsiveness
to myelin, a recent study shows that enhanced cAMP and
protein kinase A (PKA) signaling stimulates the proteolysis of
Nogo through activation of the ubiquitin ligase praja2 (Sepe
et al., 2014). cAMP is a promising target for development and
rolipram, a phosphodiesterase 4 (PDE4) inhibitor that elevates
intracellular cAMP, has been shown to enhance regeneration
and recovery after SCI in rodents (Lu et al., 2004; Nikulina
et al., 2004; Pearse et al., 2004; Kadoya et al., 2009; Costa et al.,
2013).
MAI Signaling
The actin-regulating small GTPase RhoA and downstream
effector Rho kinase (ROCK) are extensively studied mediators of
neurite outgrowth inhibition in the CNS. MAIs have been shown
to increase the levels of active GTP-bound RhoA (Dubreuil
et al., 2003) and one study suggests that the dual Rac and
Rho guanine exchange factor (GEF), Kalirin9, functionally
interacts with p75 in complex with NgR1 to stimulate RhoA
activation in response to receptor activation (Harrington et al.,
2008). Nogo also stimulates the phosphorylation and membrane
translocation of ROCK (Alabed et al., 2006). Inhibition of
ROCK stimulates neurite outgrowth on myelin and infusion
of the small molecule ROCK inhibitors Y-27632 or fasudil
into the injured rat spinal cord improves locomotor recovery
(Fournier et al., 2003; Sung et al., 2003). However, while
ROCK inhibition enhances neurite outgrowth on myelin, a
persistent myelin-induced reduction of growth relative to
enhanced baseline growth on permissive substrates is often
reported (Fournier et al., 2003; Alabed et al., 2006; Ahmed
et al., 2009), suggesting that ROCK inhibition fails to fully
de-sensitize neurons to myelin-dependent growth inhibition. It
is therefore difficult to attribute the positive effects of ROCK
inhibition in SCI to a reduction in the sensitivity of the axons
to myelin or simply to an intrinsic stimulation of outgrowth.
Our group has identified a Nogo-induced interaction between
RhoA and collapsin response mediator protein 4 (CRMP4) as a
functional signaling event that can be targeted with a competitive
peptide antagonist called C4RIP to block myelin-induced neurite
outgrowth inhibition (Alabed et al., 2007). Interestingly, C4RIP
does not enhance baseline neurite outgrowth (Alabed et al.,
2007), suggesting the specific involvement of a CRMP4-RhoA
complex engaged by MAIs. RhoA can be specifically inhibited
with the Clostridium botulinum exoenzyme C3 transferase,
which ADP-ribosylates and inactivates RhoA. Treatment of
animals with C3 improves locomotor recovery in contusion and
dorsal hemisection injury models (Boato et al., 2010). C3 has
a dual effect of enhancing neurite outgrowth in the presence
of myelin (Dergham et al., 2002) and promoting cell survival
after SCI (Dubreuil et al., 2003). Interestingly, C3 has also
been shown to stimulate neurite outgrowth and induce Erk
and Akt phosphorylation independent of its ability to inhibit
RhoA, suggesting that its mechanism-of-action has yet to be
fully elucidated (Auer et al., 2012). Detrimental effects of C3
(Fournier et al., 2003; Sung et al., 2003) observed in other studies
are potentially due to endotoxin contamination and lack of a
cell-penetrating peptide (McKerracher and Higuchi, 2006). The
positive outcomes with C3 have translated into a phase I/II
clinical trial with Cethrin (BA-210), a cell-permeable form of
C3 that is delivered locally over the dura mater in a fibrin
sealant during spinal surgery. Results from the Cethrin trial
have shown promising improvements of locomotor function
compared to historical statistics (McKerracher and Anderson,
2013).
Growth Stimulation
Recent studies have provided a strong rationale for targeting
intracellular growth regulators as a means to both drive
neuron growth and relieve sensitivity to extrinsic inhibition
of growth. Initial studies have explored strategies to stimulate
intrinsic growth potential by genetically manipulating the
expression of master regulators of cellular growth that are
considered classical tumor suppressors or oncogenes. PTEN
is a tumor suppressor that antagonizes the PI3K-Akt-mTOR
pathway (Song et al., 2012). The He lab reported an age-
associated down-regulation of mTOR activity in adult cortical
neurons and showed that conditional knockout of PTEN
and consequent increase in mTOR activity in mouse cortex
promotes regeneration of corticospinal axons after dorsal
hemisection injury (Liu et al., 2010). Another study showed
that combined deletion of PTEN and SOCS3, a negative
regulator of the JAK/STAT pathway, synergize to promote
axon regeneration in injured optic nerve (Sun et al., 2011).
These studies were noted for extraordinarily extensive long-
distance axon regeneration that had not been observed with
any prior intervention. These positive outcomes have resulted
in a greater focus on manipulation of intrinsic regulation
of neuron growth as an approach for drug development.
Chronic targeting of tumor suppressors poses a concern for
oncogenesis, but an acute regimen may be an effective strategy
to initiate a regenerative response after injury. One study
found that systemic administration of the PTEN inhibitor
bisperoxovanadium (bpVpic) twice daily for 1 week improved
forelimb motor function and was neuroprotective (Walker et al.,
2012).
A complementary strategy is to enhance the activity or
expression of growth-promoting molecules. A recent study
showed that expression of a point-mutated kinase activated
version of the B-Raf oncogene (V600E B-Raf) results in
robust regeneration of retinal axons after optic nerve injury
and regeneration of dorsal root ganglion neurons into the
dorsal root entry zone after crush injury (O’Donovan et al.,
2014). Further enhancement of regeneration was observed
with combined knockout of PTEN. How these manipulations
influence neuronal responses to extrinsic inhibition are poorly
understood. It was recently shown that codeletion of Nogo
and PTEN does not cause more corticospinal axon sprouting
after unilateral pyramidotomy, but results in improved long-
distance axon regeneration after dorsal hemisection, compared
to PTEN deletion alone (Geoffroy et al., 2015). The lack
of a combinatorial effect of PTEN and Nogo deletion on
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sprouting suggests that perhaps PTEN deletion affords maximal
de-sensitization to Nogo. One study provides evidence that
PTEN knockout neurons are less sensitive to MAG-dependent
neurite outgrowth inhibition (Perdigoto et al., 2011), while
another study has shown that Erk, a downstream effector
of Raf, can also relieve MAG-dependent inhibition (Gao
et al., 2003). It remains unclear whether these pathways
are directly involved in MAI signaling or whether they
act in parallel to alter MAI signal-transduction efficiency.
Interestingly, a recent study shows that myelin and CSPGs
stimulate the expression of pro-growth immediate early genes
through serum response factor (SRF) and Erk activation. This
may function as a protective response because expression of
constitutively active SRF was shown to overcome myelin and
CSPG—dependent neurite outgrowth inhibition (Stern and
Knoll, 2014).
Neural Stem Cells
The ability of implanted neural stem cells to survive and
functionally integrate into injured host spinal cord in rodents
also suggests that the inhibitory nature of the injured CNS
can be overcome by neurons with vigorous growth capacity
(Lu et al., 2012, 2014). In studies from the Tuszynski group,
implanted neural stem cells were shown to extend long axons
throughout the grey and white matter of transected host spinal
cords, establishing an electrophysiological bridge across the
injury. A recently published study confirmed the ability of
grafted neural stem cells to integrate into host spinal cords,
but also noted the presence of ectopic colonies of donor cells
throughout the spinal cord and brain stem in half of the animals
(Steward et al., 2014). This highlights the caution that must be
exercised in the development of neural stem cell therapies, as
implanted cells can give rise to tumors and exuberant synaptic
connections could result in unfavorable behavioral and sensory
side effects including neuropathic pain (Hofstetter et al., 2005).
Nonetheless, these studies also serve as proof-of-principle that
neurons with high growth capacity are capable of extensive
growth in the injured CNS despite the presence of inhibitory
factors.
Conclusion
Both the extrinsic and intrinsic aspects of the injury
response together forge the basis for regeneration failure.
Peripheral conditioning lesions combined with chABC and
NgR(310)ecto have been shown to provide superior benefit to
single interventions, supporting the idea that simultaneously
stimulating neuron-intrinsic growth potential and neutralizing
extrinsic inhibition can provide maximal efficacy in promoting
neural repair (Wang et al., 2012). SCI therapies that take
both of these contributors into consideration can come in
the form of drug combinations or single multi-action drugs.
The use of multi-action drugs is an attractive strategy to
simultaneously manipulate several pathophysiological features
of the injury response. For example, work from the Bradke
group has shown that local administration of low dose taxol, a
potent microtubule-stabilizing drug, exerts manifold beneficial
effects by reducing CSPG production and fibrosis, inhibiting
meningeal fibroblast migration and stimulating axon extension
after SCI (Hellal et al., 2011). A recent report from the
Bradke group shows that systemic administration of another
microtubule stabilizer, epothilone B, similarly inhibits scarring
and promotes axon regeneration (Ruschel et al., 2015). Both
drugs are approved chemotherapeutics, however epothilone
B, but not taxol, is CNS-penetrant. CNS-penetrant multi-
action pharmaceutical agents that can be given systemically
hold the most promise for translation into practical and
effective treatments for SCI. The repurposing of approved
drugs for indication in SCI is an attractive approach to achieve
accelerated approval for this serious unmet need. However,
the identification of new drugs that have multiple activities,
including modulation of astrogliosis, neuroprotection and
neurite outgrowth induction, may offer superior efficacy in
stimulating CNS repair, but will also pose challenges for safety
and tolerability.
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